Compare Texas Instruments Incorporated (TXN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Texas Instruments Incorporated vs Vertex Pharmaceuticals Incorporated — how do they compare? Texas Instruments Incorporated trades at $290.56 (market cap $258.53B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Texas Instruments Incorporated is far larger — about 2.1× Vertex Pharmaceuticals Incorporated's market cap, and Texas Instruments Incorporated pays a 2% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TXN | VRTX | |
|---|---|---|
Market Cap | $258.53B | $121.95B |
Sector | Technology | Health |
52-Week High | $332.35 | $529.59 |
52-Week Low | $153.33 | $366.54 |
Enterprise Value | $267.48B | $116.69B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Texas Instruments (TXN) trades at $284.02, down 2.47% over 24 hours, with technical signals leaning bearish. The company reported mixed recent earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue and net income have shown volatility, with 2025 figures at $17.68B and $5.00B respectively. Analysts maintain a consensus Buy rating with a $313.05 price target, indicating potential upside. Recent CFO transition news and AI-driven demand in data centers are key developments.
Outlook remains cautiously optimistic given strong profitability margins and analyst support, but risks include elevated valuation multiples and competitive pressures in the semiconductor sector. The stock's current price near support at $281 suggests a critical level for near-term direction.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
